



INNOVATION AND DIGITAL SOLUTIONS FOR SAFER THERAPY
IMPLEMENTATIONS: A NARRATIVE REVIEW OF DIGITAL HEALTH
TECHNOLOGIES, CLINICAL DECISION SUPPORT, AND DATA-DRIVEN
APPROACHES TO REDUCING THERAPY-RELATED HARM

K. Jayasri Naga Suryamukhi¹, P. Maitreya^{2,*}

¹Department of Pharmacy Practice, Sir C. R. Reddy College of Pharmaceutical Sciences, Eluru – 534007, Andhra Pradesh, India

²Department of Pharmacy Practice, Sir C. R. Reddy College of Pharmaceutical Sciences, Eluru – 534007, Andhra Pradesh, India

ABSTRACT

Objective: To synthesise peer-reviewed and authoritative grey literature on digital innovation for safer therapy implementation, spanning clinical decision support, medication-administration technology, artificial-intelligence-enabled pharmacovigilance, remote observation, and pharmaceutical supply-chain traceability, and to propose an integrative framework for organising investment and evaluation in this domain.

Methods: A narrative, integrative review of structured evaluations, scoping evaluations, primary studies, and authoritative grey literature (WHO, AHRQ, FDA) across five technology domains, synthesised without official risk-of-bias scoring or pooled effect estimation.

Results: Digital instruments dependably boost process-of-care measures; for instance, decreasing prescribing errors and enhancing guideline adherence; but show more modest and varied effects on hard patient results such as negative drug events, an asymmetry that recurs across almost every domain examined. Persistent cross-cutting obstacles contain alert fatigue and automation bias, poor compatibility, algorithmic bias and limited exterior validation of artificial-intelligence models, cybersecurity and privacy risk, and irregular regulatory frameworks for software as a medical device. A five-layer conceptual framework; data foundation, point-of-care execution, tracking and feedback, analytics and learning, and management; are proposed to help organise digital-safety investment and evaluation.

Conclusion: Digital solutions are essential but not sufficient for safer therapy: technology delivers safety advantage exclusively when embedded within sound sociotechnical systems, thorough and meticulous validation, and continuous human-centred design, and implementation quality; not technical sophistication; most consistently distinguishes successful from disappointing deployments.

Keywords: patient safety; digital condition; clinical decision support systems; medication errors; artificial intelligence; pharmacovigilance; remote patient observation; digital therapeutics; blockchain; condition informatics

Address for Correspondence:

K. Jayasri Naga Suryamukhi, Department of Pharmacy Practice, Sir C. R. Reddy College of Pharmaceutical Sciences, Eluru – 534007, Andhra Pradesh, India. Tel.: +91 8919149792. E-mail: jayasreekarri768@gmail.com

Abbreviations: CPOE, computerised provider order entry; CDSS, clinical decision support system; BCMA, barcode medication administration; DERS, dose-error-reduction system; EHR, electronic condition record; ADE, negative and damaging drug occurrence; ADR, negative and damaging drug reaction; AI, artificial intelligence; ML, machine learning; NLP, natural language processing; RPM, remote patient observation; DTx, digital therapeutics; GVP, Good Pharmacovigilance Practice; DSCSA, Drug Supply Chain Security Act; IoT, Internet of Things; WHO, World Health Organization; FDA, U.S. Food and Drug Administration; AHRQ, Agency for Healthcare Research and Quality; PSNet, Patient Safety Network.

1. INTRODUCTION AND BACKGROUND

Modern therapeutics deliver enormous advantage, yet the identical intricacy that enables precise, individualised care moreover creates many and various opportunities for error. Every step of the therapy pathway; diagnosis, prescribing, transcription, dispensing, administration, and ongoing observation; depends on the correct transfer of information between various and several people, systems, and settings. The World Health Organization (WHO) has repeatedly identified medication-related detriment as a top patient-safety priority, estimating that dangerous medication practices and errors are a leading reason of avoidable injury in condition systems internationally, and launching the Medication Without Harm initiative with a stated worldwide ambition of decreasing serious, avoidable medication-related detriment [1,2].

Landmark U.S. analyses have suggested that medical error, comprising harmful and detrimental and damaging and detrimental drug-related events, may represent a significant contributor to mortality and has consequently prompted substantial investment in quality improvement [3]. The

often-cited declaration that medical error is the “third leading reason of demise” in the United States originates from a 2016 analysis by Makary and Daniel. However, the methodology used and the extrapolation of results from limited hospital data to a national mortality approximation have been thoroughly criticised in succeeding literature. Therefore, this approximation should be viewed as a broadly cited but contested estimation alternatively than a definitive or established ranking of reasons of demise. [4]

Digital condition technologies have emerged as a central plan for closing this safety gap. Electronic condition records (EHRs), computerised provider order entry (CPOE), clinical decision support systems (CDSS), barcode medication administration (BCMA), smart infusion pumps, and; more recently; artificial intelligence (AI)-enabled pharmacovigilance, remote patient observation (RPM), digital therapeutics, and blockchain-based traceability instruments all promise to reduce the probability that an error attains a patient, or to detect detriment previously when it does occur. Global regulators, comprising the U.S. Food and Drug Administration (FDA) through its recently established Digital Health Advisory Committee, have begun to formalise evaluation pathways for these instruments, indicating both their pledge and the need for oversight [5].

This review addresses an easy and straightforward but consequential query: what does the evidence say about how digital innovation contributes to safer therapy implementation, and under what conditions does that commitment translate into quantifiable advantage for patients? The review is written for clinicians, health-system leaders, condition informaticians, pharmacists, and policy audiences seeking an ordered and methodical, evidence-anchored overview of the domain alternatively than a narrow technical audience.




Fig. 1: Composite adoption index of digital safety technologies across hospital and health-system reports (conceptual synthesis of adoption patterns described across the reviewed literature; not a pooled survey statistic; marked as illustrative and not to be read as measured data).

As Figure 1 illustrates conceptually, adoption of digital safety technologies changes significantly across domains, with clinical decision support and barcode/smart-pump administration technologies reported as the most broadly diffused and blockchain-enabled traceability the least, a pattern steady and regular with the relative maturity of each area discussed in Sections 4 through 8.

1.1 Scope and Objectives

The objectives of this review are threefold:

- To synthesise contemporary and ongoing evidence on the effectiveness, advantages, and limitations of important and significant types of digital solutions used to make therapy delivery safer.
- To identify recurring cross-cutting obstacles; technical, human-factors, moral, and regulatory; that establish whether digital instruments attain their intended safety advantage.
- To propose an integrative conceptual framework and a forward-looking study and policy agenda that can direct investment and evaluation.

The review covers five main technology domains; clinical decision support and order-entry systems; medication-administration technologies (barcode scanning and smart infusion pumps); AI/ML-enabled pharmacovigilance; telehealth, remote patient observation, and digital therapeutics; and blockchain-enabled pharmaceutical supply-chain traceability; while furthermore tackling cross-cutting problems such as alert fatigue, compatibility, algorithmic bias, and cybersecurity that cut across every domain, and a further segment considering the Indian regulatory and implementation setting specifically.

2. METHODOLOGY OF THIS REVIEW

This is a narrative, integrative review instead than an official structured review or meta-analysis; no clinical or statistical assertions herein should be understood as a pooled effect approximation. The review draws on peer-reviewed structured and orderly evaluations, scoping assessments, primary studies, clinical-informatics literature, and authoritative grey literature (WHO, AHRQ PSNet, FDA) identified through ordered and methodical searches of biomedical and

technology databases and reference monitoring. Priority was given to methodical evaluations and new and fresh (2020–2026) primary literature where available, supplemented with essential prior studies that continue central to the area (for case, the initial description of CDSS architecture and the broadly cited characterisation of medical error as a reason of mortality) [3,4,8].

Because the underlying literature is varied in design, outcome definition, and setting, this review adopts a narrative synthesis approach organised by technology domain, with a concluding attempt at cross-domain integration through a conceptual framework (Section 10). Figures displaying adoption trends, error-stage distributions, and alert-override trends are representative syntheses constructed to visualise patterns reported qualitatively and quantitatively across the examined sources; they are not derived from a single primary dataset and should be read as conceptual aids instead than as new empirical results.

2.1 Inclusion Considerations

- Studies and evaluations tackling digital or technological interventions intended to improve the safety of medication or broader therapy delivery.
- English-language structured and orderly evaluations, scoping assessments, primary study, and authoritative policy or regulatory direction.
- Publications spanning hospital, primary-care, community-pharmacy, and home/remote-care settings.

2.2 Limitations of the Review Approach

As a narrative review, this work does not apply official risk-of-bias scoring to individual primary studies and can not omit publication bias in the underlying literature. Rapid technological change furthermore means that some cited instruments and platforms will develop or be superseded quickly; conclusions are hence framed around durable principles (workflow integration, human-factors design, validation, management) instead than explicit and defined products.

3. THE BURDEN OF THERAPY-RELATED HARM

Medication errors can occur at any point in the medication-use process, and empirical assessments have found that prescribing errors solely occur in up to approximately 11% of all prescriptions, with inpatient studies reporting overall medication error rates surpassing 5%, of which near to half occur at the ordering stage [6].

The strain is similarly substantial in outcome conditions: unfavorable drug events have been calculated in U.S. hospital-based analyses to injure or contribute to the demise of multiple hundred thousand hospitalised patients annually, with related costs projected in the millions of dollars per hospital each year [3,6]; as with the mortality-ranking figure discussed in Section 1, such extrapolated national totals should be read as order-of-magnitude estimates instead than precise counts.

Table 1: Principal categories of therapy-related harm by medication-use process stage, with the digital mitigation strategy most directly addressing each

Process stage	Principal harm category	Digital mitigation strategy	Section
Prescribing / ordering	Dosing errors, drug–drug and drug–allergy interactions	CPOE, CDSS [6,9]	4
Transcription	Illegible or mistranscribed orders	Structured e-prescribing, CPOE [8]	4
Dispensing	Wrong drug / wrong strength selection	BCMA, pharmacy CDSS [13]	4–5
Administration	Wrong-patient, wrong-time, wrong-rate errors	BCMA, smart infusion pumps [14,15]	5

Process stage	Principal harm category	Digital mitigation strategy	Section
Post-market monitoring	Under-detected adverse drug reactions	AI/ML pharmacovigilance [19,23]	6
Ongoing therapy / home care	Non-adherence, delayed deterioration	RPM, digital therapeutics [25,26]	7
Supply chain	Substandard or falsified product reaching the patient	Blockchain traceability [30,32]	8

Table 1 summarises the main groups of therapy-related damage addressed by the digital solutions examined in this article, mapped to the process stage at which each is

most probable to originate and the digital intervention category most directly aimed at decreasing it, as discussed further in Sections 4 through 8.

Fig-2: Conceptual Schematic




Fig. 2: Distribution of medication errors by process stage, before and after digitally supported workflows (illustrative synthesis of patterns reported across the reviewed literature; underlying values are representative rather than pooled statistics).

As Figure 2 illustrates conceptually, the literature consistently finds that digitally supported workflows shift and, in most stages, reduce the proportion of errors relative to standard paper-based procedures; most markedly at the transcription and dispensing stages, where systematic data capture eliminates handwriting- and re-entry-related error, and less markedly at the observation stage, where damage detection still depends heavily on clinical judgement and data totality [6,8].

4. COMPUTERISED PROVIDER ORDER ENTRY AND CLINICAL DECISION SUPPORT SYSTEMS

Clinical decision support systems (CDSS) are widely specified as any system designed to improve clinical decision-making related to diagnostic or therapeutic operations of care by utilizing patient-specific data; diagnoses, laboratory outcomes, present medications, or combinations of these; to deliver recommendations at the point of care. First described in recognisable modern form more than forty years ago and formalised as an actionable e-prescribing framework in the

mid-2000s, CDSS have become one of the most thoroughly examined digital safety interventions [7,8]. An overview of twenty structured assessments including 237 randomised controlled trials and 176 non-randomised studies found that CDSS considerably enhanced process-of-care results; such as prescribing appropriateness and adherence to dosing advice; in 75% of the studies examined, but considerably enhanced hard patient

This asymmetry; robust effects on process, weaker and more mixed effects on results; recurs across the CDSS literature and are a central theme of this review. A more latest methodical and organized review concentrated specifically on older adults, a population disproportionately impacted by polypharmacy and negative and damaging drug events, similarly found that CDSS show potential to reduce potentially inappropriate medications but that effectiveness for this category remains doubtful and unsure and extremely dependent on implementation setting [10].

A scoping review of CDSS for drug prescription and therapy optimisation between 2017 and 2022 concluded that the traits most consistently associated with effective implementations included integration into existing prescriber workflow, specificity and clinical relevance of warnings, and participation of pharmacists in the design and management of the rule foundation [11,12].

4.1 Mechanisms of Benefit

- Automated examination of dose ranges, renal/hepatic dose modification, and maximum daily dose against patient-specific parameters.
- Real-time screening for drug–drug, drug–allergy, and drug–disease interactions at the point of prescribing.
- Duplicate-therapy and duplicate-order detection across care shifts.
- Structured order sets and default values that lower reliance on free-text or memory-based prescribing.
- Feedback loops (for case, pharmacist co-signing prompts) that route higher-risk orders for extra review.

4.2 Community Pharmacy and Ambulatory Applications

CDSS application is not restricted to hospitals. A randomised cross-over trial of 71 community pharmacists found that medication evaluations performed without CDSS support took between approximately 26% and 31% longer than assessments performed with CDSS support, while CDSS employ furthermore supported detection of a comparable or greater number of clinically relevant drug-related issues; evidence that decision support can concurrently improve productivity and thoroughness in ambulatory settings [13].

Table 2: Selected Systematic-Review Evidence on CDSS and Medication Safety

Source	Design	Principal finding
Jia et al. [9]	Overview of 20 SRs (237 RCT, 176 non-RCT)	75% of studies show process benefit; 20% show hard-outcome benefit
Ng et al. [10]	Systematic review, older adults	Reduced potentially inappropriate medications; outcome effect uncertain
Lampe et al. [12]	Systematic review, primary/long-term care	Heterogeneous outcome measurement limits synthesis
Kane-Gill et al. [13]	RCT, 71 community pharmacists	26–31% faster medication reviews with CDSS support

5. BARCODE MEDICATION ADMINISTRATION AND SMART INFUSION PUMP TECHNOLOGY

If CDSS primarily aims at the prescribing stage, barcode medication administration (BCMA) and smart infusion pumps target the point where an error most directly attains the patient: administration. BCMA necessitates clinicians to scan a patient identifier and a medication barcode before administration, cross-checking both against the active order to intercept wrong-patient, wrong-drug, or wrong-time errors before they occur.

Smart infusion pumps incorporate dose-error-reduction systems (DERS) built around a customizable drug library that encodes organisation-specific limits on concentration, rate, dose, and span for each medication and care area; the pump can then warn or hard-stop an infusion programmed outside those limits.

Evidence on effectiveness is encouraging but qualified. A broadly cited review concluded that smart pumps most dependably reduce administration errors when combined with barcode scanning or when configured with 'hard' (non-overridable) alternatively than 'soft' dosing limits; smart pumps used in separation, without barcoding, do not dependably prevent wrong-patient errors and continue vulnerable to workaround behaviour such as bypassing the drug library [14].

A study of smart-pump implementation for high-alert sedative and analgesic infusions in critically sick patients found that, after implementation, adherence with programming through the drug library reached 67%, and the pumps intercepted 398 infusion-related programming errors that would otherwise have led to erroneous drug delivery [15].

5.1 Interoperability as the Next Frontier

A recurring theme in more new and fresh literature is that BCMA, smart pumps, and the EHR were historically built as separate systems; next-generation implementations

increasingly support bidirectional, auto-programming compatibility, in which scanning a medication barcode pre-populates infusion parameters directly into the pump, which the clinician then confirms instead than manually re-entering [16].

This closed-loop design; linking order, confirmation, and administration; is evaluated by various authors to represent the pragmatic endpoint for removing manual transcription error at the bedside, although achieving it necessitates substantial capital investment and cross-vendor integration work that several organisations have not yet finalized [17,18].

5.2 Persistent Limitations

- Technology captures data solely while a medication is actively infusing; it can not detect a sorted medication that was never hung, or a delay in initiating therapy.
- Workarounds; for instance, scanning a barcode from a wristband photocopy taped to the bed rail alternatively than the patient's real and genuine wristband; can silently defeat the safety check.
- Medications with various clinical indications may still need manual option within the drug library, reintroducing a chance for error even within an ostensibly 'smart' system.
- Alert design matters: pumps configured with extreme and unreasonable soft-limit cautions can generate their own form of alert fatigue, discussed further in Section 11.

6. ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN PHARMACOVIGILANCE

Pharmacovigilance; the science of detecting, assessing, and preventing harmful and detrimental effects of medicines after they reach the market; has historical roots in the thalidomide tragedy of 1961, which prompted the WHO Pilot Research Project for International Drug Monitoring in 1968 and founded the foundations of modern post-market drug-safety monitoring.

Traditional pharmacovigilance relies significantly on spontaneous reporting, which is known to under-capture negative and damaging events; AI and machine learning are increasingly deployed to enhance this system by mining organized electronic condition records, unstructured clinical notes, and social-media or patient-forum content for safety signals that might otherwise go unreported [19].

A structured review of AI applications for forecasting negative and damaging drug reactions in hospitalised patients found that machine-learning and deep-learning methods consistently enhanced the accuracy and productivity of adverse-event detection relative to manual or rule-based procedures, incorporating successful application of AI-assisted trigger instruments in emergency-department settings [20,21].

A scoping review issued in 2025 similarly concluded that most present AI applications in this space focus on the post-market pharmacovigilance phase, drawing on EHR data, real-world evidence, and patient demographics to identify rare or delayed unfavorable reactions that pre-market trials; restricted by smaller sample sizes and shorter follow-up; are improbable to detect [22].

6.1 Techniques in Use

- Natural language processing (NLP) to extract adverse-event mentions from unstructured clinical notes, discharge synopses, and patient-reported writing.
- Supervised machine-learning classifiers trained to flag laboratory or vital-sign

patterns steady and regular with drug-induced organ injury (for illustration, nephrotoxicity or hepatotoxicity).

- Deep-learning architectures applied to large-scale insurance-claims or EHR datasets to detect drug–drug interaction signals not captured by static interaction databases.
- Bayesian network and probabilistic causality-assessment instruments intended to reduce subjectivity in individual case-safety-report review.

A narrative review describing pragmatic experience with an expert-defined Bayesian network instrument in a real-world pharmacovigilance centre reported that the instrument meaningfully reduced case-processing time while maintaining high concordance with expert causality evaluations, showing a sensible, hybrid path between fully automated and entirely manual review [23].

6.2 Known Limitations

Despite this pledge, methodical assessments converge on a uniform and unchanging set of caveats: AI-based pharmacovigilance instruments rely heavily on data quality and totality; most issued models have been assessed on a limited number of data sources and lack outside validation across mixed and assorted populations and condition systems; and regulatory approval and explainability continue unresolved obstacles to routine adoption under existing Good Pharmacovigilance Practice (GVP) frameworks [24,25].

Table 3: AI/ML Techniques Used in Pharmacovigilance and Their Primary Function

Technique	Primary function	Representative source
Natural language processing	Extract adverse-event mentions from unstructured text	[19,22]
Supervised ML classifiers	Flag lab/vital-sign patterns consistent with organ injury	[20]
Deep learning on EHR/claims	Detect drug–drug interaction signals	[21,22]
Bayesian causality networks	Support case-level causality assessment	[23]

7. TELEHEALTH, REMOTE PATIENT MONITORING, AND DIGITAL THERAPEUTICS

The COVID-19 pandemic accelerated adoption of telehealth and remote patient observation (RPM), and utilisation has remained significantly elevated since; U.S. Medicare claims data, for instance, showed an about 555% increase in remote-monitoring application between February 2020 and September 2021, with nineteen-fold increase from the inception of the relevant reimbursement programme in 2019 through December 2021 [25].

A methodical and organized review of RPM interventions supporting the transition from inpatient care to the home setting, drawing on 29 studies across 16 countries, examined seven groups of RPM technology; communication instruments, computer-based systems, smartphone applications, web portals, augmented clinical devices, wearables, and standard intermittent-monitoring instruments; and found generally favourable effects on safety, adherence, and quality-of-life results, albeit with substantial heterogeneity in intervention design and outcome measurement [25].

Condition-specific evidence reinforces this picture. Analyses of Medicare populations found that greater telemedicine and RPM utilisation were associated with enhanced medication adherence for diabetes and hyperlipidaemia, fewer emergency-department visits, and increased optional outpatient care, while RPM in hypertension and heart failure has been linked to better blood-pressure and glycaemic control alongside reduced hospital readmission [26].

A twelve-month randomised trial of remote tracking in hypertensive patients (the PROSIT study) found that groups obtaining

digital remote-monitoring support attained substantially greater confirmed medication-adherence scores, more regular and recurring initial therapeutic modification, and; over follow-up; decreases in the number of prescribed antihypertensive medications alongside favourable changes in cardiac and renal parameters relative to a control category without ongoing digital support [25,26].

7.1 Wearables and Continuous Physiological Monitoring

Wearable sensors extend RPM by continuously capturing physiological signals; heart rate and rhythm, oxygen saturation, activity, and increasingly glucose or blood pressure; outside the clinical encounter. Reviews of wearable validation studies observe growing evidence of clinical-grade accuracy for selected consumer and prescription-grade devices in cardiac rhythm observation and continuous glucose observation, alongside caution that device accuracy, algorithmic drift, and false-alarm rates differ substantially by device class and population [27,29].

7.2 Digital Therapeutics

Digital therapeutics (DTx); software-based interventions intended to prevent, manage, or treat a medical state, frequently subject to regulatory clearance in a manner similar and comparable to a drug or device; represent a distinct but related category. Regulatory bodies comprising the FDA have shifted to formalise oversight of these instruments through dedicated advisory systems tackling AI/ML-enabled devices, digital therapeutics, and remote-monitoring technologies jointly, indicating recognition that software-delivered interventions raise safety and effectiveness queries equivalent to those long applied to pharmaceuticals and devices [5,28].

Table 4: Categories of Remote and Digitally Delivered Monitoring Technologies

Category	Example modality	Reported effect
Communication tools	Video/telephone follow-up	Improved adherence, fewer ED visits [25,26]

Category	Example modality	Reported effect
Wearable sensors	Cardiac rhythm, SpO ₂ , continuous glucose	Clinical-grade accuracy for selected devices [27]
Smartphone applications	Symptom/PRO tracking	Favourable safety and QoL effects [25]
Digital therapeutics (DTx)	Software-based clinical intervention	Regulatory pathways under active development [5,28]

8. BLOCKCHAIN AND SUPPLY-CHAIN TRACEABILITY FOR MEDICINE SAFETY

Therapy safety depends not solely on right prescribing and administration but on the prior assurance that the medicine itself is genuine, correctly devised, and has been archived within suitable conditions throughout distribution. Substandard and falsified medicines continue a severe problem, though the scale must be specified carefully. The WHO's 2017 study on the public condition and socioeconomic impact of substandard and falsified medical products estimates that approximately one in ten medical products circulating specifically in low- and middle-income countries is substandard or falsified; this is not a worldwide supply-chain figure and should not be generalised to the worldwide medicine supply as a whole [30].

Modelling commissioned by WHO from the University of Edinburgh and the London School of Hygiene and Tropical Medicine calculated that substandard and falsified antibiotics and antimalarials specifically in sub-Saharan Africa are associated with tens of thousands of avoidable childhood pneumonia and malaria deaths each year; orders of magnitude smaller than, and confined to precise product classes and regions, instead than the unqualified worldwide mortality figures occasionally circulated in secondary literature [30].

Blockchain technology, characterised by decentralised, tamper-evident, time-stamped transaction records, has been proposed as a mechanism to establish end-to-end traceability across production, distribution, and dispensing. A structured review of blockchain applications in the

pharmaceutical sector identified counterfeit-drug avoidance, product distribution monitoring, and safety/security assurance as the three primary application areas reported in the literature [31].

Regulatory frameworks have shifted in parallel: the U.S. Drug Supply Chain Security Act (DSCSA) necessitates distributors to verify returned-product authenticity and, eventually, to support unit-level track-and-trace of prescription drugs, while global efforts such as the Global Traceability Standard for Healthcare pursue comparable goals across jurisdictions [32].

8.1 Emerging Architectures

- Blockchain combined with Internet of Things (IoT) temperature sensors to create an immutable cold-chain record for temperature-sensitive biologics and vaccines [34].
- Smart-contract-triggered warnings when a shipment's recorded conditions or custody chain deviates from pre-agreed parameters.
- QR-code and blockchain-linked product confirmation permitting patients or pharmacists to verify a product's provenance at the point of dispensing.
- Hybrid architectures merging blockchain, cloud storage, and encryption to balance transparency with the privacy responsibilities of participating manufacturers and distributors [35].

A latest and current framework paper describing a blockchain-enabled drug supply-chain system reported that merging blockchain, smart contracts, and QR-code traceability enhanced the precision of drug dispensing while supporting real-time validation of authenticity across the distribution chain, demonstrating the

pragmatic direction of contemporary and ongoing study even though most released architectures persist at model or pilot stage alternatively than large-scale deployment [33].

8.2 Limitations

Reviewers consistently flag scalability, cross-organisational management, integration with existing enterprise-resource-planning and pharmacy systems, and the cost and intricacy of achieving industry-wide involvement as the chief hurdles preventing blockchain traceability from moving beyond pilot implementations toward the prevalent system that would be required to meaningfully reduce substandard- and falsified-medicine detriment [34,35].

9. DIGITAL HEALTH SAFETY IN THE INDIAN CONTEXT

The domains examined in Sections 4 through 8 are drawn mainly from North American, European, and East Asian literature. India's scale, its distinct regulatory architecture, and its irregular digital system across urban and rural settings make it an informative extra case for this journal's readership, and various India-specific initiatives map directly onto the technology domains discussed above.

9.1 Interoperability Infrastructure: *Ayushman Bharat Digital Mission*

India's Ayushman Bharat Digital Mission (ABDM), launched nationally in 2021, together with the accompanying Health Data Management Policy, provides the interoperability substrate — unique health identifiers, a health facility registry, and consent-based health-record linkage — that Section 10 of this review identifies as the foundational Layer 1 on which point-of-care and analytics tools depend [36]. As in the high-income-country CDSS and BCMA literature reviewed in Sections 4 and 5, the practical safety benefit of ABDM-linked systems will depend on whether individual facilities' CDSS and prescribing systems are actually connected to it, rather than on registration alone.

9.2 Remote Care Infrastructure: *Telemedicine Practice Guidelines and eSanjeevani*

The Telemedicine Practice Guidelines distributed by India's Ministry of Health and Family Welfare in 2020 founded the legal and clinical framework for remote consultation, and the eSanjeevani platform has since become the chief national telemedicine service built on that framework [37]. eSanjeevani denotes a distinctive form of the remote patient observation and telehealth technologies discussed in Section 7: instead than being led by individual condition systems or commercial RPM vendors, it is operated as centralised public system, which changes both the compatibility difficulty and the management model relative to the mainly institution-led deployments described in the global literature.

9.3 Pharmacovigilance Infrastructure: *PvPI and the Indian Pharmacopoeia Commission*

The Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission, is the national adverse-drug-reaction reporting system into which any AI-based signal-detection instrument of the kind examined in Section 6 would need to integrate [38]. Because PvPI relies significantly on spontaneous reporting from a big and substantial and varied network of reporting centres, the identical under-capture limitation discussed in Section 6 applies, and arguably applies with greater force given reporting-density variation across states; AI-assisted signal detection drawing on ordered and methodical EHR and pharmacy data could plausibly enhance PvPI's capability in the way described for other condition systems in Section 6, though this application has not yet been assessed at national scale in the literature examined here.

9.4 Supply-Chain Traceability: *The Drugs and Cosmetics Act and DGFT Track-and-Trace*

India's equivalent to the U.S. Drug Supply Chain Security Act discussed in Section 8 is found in the Drugs and Cosmetics Act, 1940,

and its associated Rules, which define and prohibit the manufacture and sale of spurious and adulterated drugs, together with the Directorate General of Foreign Trade (DGFT) track-and-trace condition mandating barcoding and serialisation for pharmaceutical exports [39]. As India is among the world's biggest generic-medicine exporters, the export-facing DGFT necessity is, at present, more mature than equivalent domestic-market traceability system, which parallels the pilot-stage domestic deployment pattern described for blockchain traceability more generally in Section 8.2.

9.5 Constraints on CDSS Deployment in Indian Hospitals

The CDSS evidence examined in Section 4 originates mainly from condition systems with near-universal electronic prescribing. Electronic prescribing penetration in Indian hospitals remains markedly irregular across public, private, tertiary, and secondary-care settings, which constrains large-scale CDSS deployment of the kind examined in Section 4 to a smaller subset of organizations than in the condition systems that dominate the issued evidence foundation; this gap denotes both a limitation on the generalisability of the

global CDSS literature to the Indian setting and a precise and particular inquiry and investment priority, addressed further in the Future Directions part (Section 13.7).

10. A LAYERED CONCEPTUAL FRAMEWORK FOR DIGITALLY ENABLED SAFER THERAPY

The domains examined above are often discussed in separation within the literature, yet in practice they function as an interdependent system: an AI pharmacovigilance model is solely as dependable as the EHR data feeding it; a smart infusion pump's dose-error-reduction system is exclusively as protective as the accuracy of the drug library configured by pharmacy management; and blockchain traceability solely closes the safety loop if it connects, eventually, to the point-of-care confirmation performed through barcode scanning.

To help organisations consider about digital-safety investment holistically instead than as a series of disconnected point solutions, this review proposes a five-layer conceptual framework, illustrated in Figure 3.

Fig-3: Conceptual Schematic

Safety failures often originate at the interfaces between layers, not within a single layer




Fig. 3: A layered conceptual framework for digitally enabled safer therapy implementation (conceptual synthesis, synthesised from the technology domains and governance considerations reviewed in Sections 4–9 and 12).

10.1 Description of the Layers

- Layer 1; Data and Identification Foundation: interoperable EHR data structures, unique patient and device identifiers, and (increasingly) blockchain-based product traceability provide the substrate on which every greater layer depends.
- Layer 2; Point-of-Care Execution: CPOE, CDSS warnings, BCMA, smart infusion pumps, and e-prescribing intervene at the instance a therapy decision is made or a medication is physically administered.
- Layer 3; Monitoring and Feedback: remote patient tracking, wearables, digital therapeutics, and organized patient-reported results extend monitoring beyond the point of care into the patient's ongoing course of therapy.
- Layer 4; Analytics and Learning: AI/ML-enabled pharmacovigilance, predictive risk modelling, and natural-language-processing-based signal detection sum data across Layers 1–3 to identify

patterns invisible at the level of any single encounter.

- Layer 5; Governance and Regulation: oversight of software as a medical device, Good Pharmacovigilance Practice adherence, data-protection law, and organisational audit handles bind the other four layers together and determine whether innovations can be trusted and sustained.

A fundamental implication of this framework is that safety failures frequently originate not within a single layer but at the interfaces between layers; for case, when a CDSS warning (Layer 2) is generated from stale allergy data (Layer 1), or when a predictive risk model (Layer 4) has no specified management pathway (Layer 5) for acting on a flagged patient. Evaluation and investment methods that consider solely one layer in separation is consequently expected to under-detect the true sources of residual risk.

11. CROSS-CUTTING CHALLENGES: ALERT FATIGUE, BIAS, INTEROPERABILITY, AND CYBERSECURITY

11.1 Alert Fatigue and Automation Bias

Alert fatigue; the phenomenon by which clinicians become desensitised to, and habitually override, a high volume of low-value warnings; is among the most consistently reported accidental outcomes of CDSS deployment. Observational analyses have reported that clinicians override safety notifications between about 49% and 96% of the time, and that some clinicians encounter one hundred to two hundred warnings per day [40,41].

A retrospective cohort analysis of ambulatory CDSS application found that minimizing within-patient recurrence of the identical warning; alternatively than simply decreasing overall alert volume; was an especially hopeful and encouraging target for lowering override rates, and did not find

robust evidence that raw workload solely drove desensitisation, suggesting that alert design and redundancy, not merely alert quantity, are central drivers of the phenomenon [42].

A 2019 structured review concluded that alert fatigue can be meaningfully reduced through interaction design (for case, tiering warnings by gravity so that exclusively the most clinically notable disturbances are hard stops) and through tailoring alert material and delivery to explicit and defined clinical functions, alternatively than displaying identical warnings to every user regardless of setting [42].

A 2026 qualitative study employing a human-factors approach similarly found that alert fatigue is a dynamic, context-dependent experience shaped by cognitive load, desensitisation, and system-level aspects; and cautioned that as AI-based warnings become more widespread, high positive-predictive-value warnings may be superficially processed and automatically accepted due to automation bias, a distinct but related risk to habitual override [43].

Fig-4: Conceptual Schematic




Fig. 4: Illustrative trend in clinical decision support alert override rates, reflecting patterns described in the alert-fatigue literature and the more recent introduction of tiered and AI-refined alerting strategies (conceptual synthesis, not a pooled statistic).

Table 5: Strategies for Mitigating Alert Fatigue Reported in the Reviewed Literature

Strategy	Mechanism	Source
Reduce within-patient repetition	Suppress duplicate alerts for the same patient/order	[42]
Tiering by severity	Reserve hard stops for the most clinically significant alerts	[42]
Role-based tailoring	Route different alert types to the clinician best placed to act	[42]
Human-factors redesign	Address cognitive load and context, not volume alone	[43]

11.2 Interoperability

Nearly every domain examined in this article depends on data moving dependably between systems built by distinct vendors, on dissimilar technical standards, and frequently procured at distinct points in an organisation's history. Reviews of smart-pump compatibility mention that although most hospitals adopting total and whole EHR–BCMA–pump integration document beneficial experiences and do not plan to remove it, numerous organisations still function siloed systems because integration work is postponed until existing equipment contracts expire [16].

11.3 Algorithmic Bias and Validation

AI/ML models used in pharmacovigilance and predictive risk scoring are normally trained on data from explicit condition systems or populations; multiple evaluations caution that most issued models lack outside

validation across mixed and assorted populations, raising the possibility that a model performing well in one setting under-detects risk in a population it was not trained on. Explainability is a related concern; clinicians and regulators are understandably reluctant to act on a flagged safety signal that can not be understood or audited [24,25].

11.4 Cybersecurity and Data Privacy

Connected infusion pumps, RPM devices, and blockchain nodes all expand an organisation's digital attack surface. While cybersecurity was not a primary focus of most safety-outcome studies reviewed here, it is increasingly treated by regulators and health-system leaders as inseparable from clinical safety, since a compromised connected device or falsified data record can directly translate into physical patient harm rather than remaining a purely informational risk.




Fig. 5: Commonly reported barriers to safe digital therapy implementation, ranked by relative severity as synthesised across the reviewed literature (illustrative synthesis).

12. REGULATORY AND GOVERNANCE CONSIDERATIONS

Regulatory frameworks for digital-safety technologies are developing swiftly and unevenly across jurisdictions. In the United States, the FDA convened the inaugural meeting of its Digital Health Advisory Committee on 20–21 November 2024 to consider total-product-lifecycle aspects for generative-AI-enabled devices, indicating recognition that AI/ML-enabled devices, virtual actuality, wearables, digital therapeutics, and remote patient observation increasingly need dedicated evaluation frameworks distinct from conventional and customary drug or device pathways [5].

Reimbursement policy is a related lever: U.S. Medicare fee-schedule changes have developed dedicated reimbursement codes for remote therapeutic tracking and FDA-cleared digital behavioural-health instruments, a step broadly examined as essential and required to move digital therapeutics from pilot funding toward sustainable, broad-based clinical application [26].

In pharmacovigilance specifically, AI-based instruments must function within existing Good Pharmacovigilance Practice (GVP) necessities, which mandate that automated systems be thoroughly confirmed, clear, and managed within an organisation's overall quality system instead than dispatched as an unaudited 'black box'; a necessity that various of the sources examined suggest present AI techniques can meet, supplied validation and documentation practices keep speed with model development [23,24].

For pharmaceutical supply-chain traceability, the U.S. Drug Supply Chain Security Act and global counterparts such as the Global Traceability Standard for Healthcare; and, in India, the Drugs and Cosmetics Act and DGFT track-and-trace condition discussed in Section 9.4; provide the regulatory scaffolding against which blockchain and other track-and-trace technologies are being deployed, although total and whole unit-level compatibility across the whole and complete chain, from manufacturer to dispensing pharmacy, remains an ongoing implementation difficulty instead than an accomplished state [32,39].

12.1 Governance Recommendations Emerging from the Literature

- Establish multidisciplinary management (informatics, pharmacy, nursing, medicine, and patient representation) for the ongoing review and pruning of CDSS warning rules.
- Require documented exterior validation, comprising performance across demographic and clinical subgroups, before deploying AI/ML pharmacovigilance or risk-prediction instruments in routine care.
- Align procurement specifications for infusion pumps, BCMA, and EHR systems around compatibility standards at the outset, instead than retrofitting integration after independent acquisition decisions.
- Treat cybersecurity risk assessment as a component of clinical safety review for any linked and associated device or blockchain-enabled supply-chain system, not entirely as an information-technology concern.
- Build ordered and methodical processes for frontline clinician feedback into the lifecycle of every digital safety instrument, given the robust and repeated literature discovering that workflow suitable determines real-world effectiveness.

13. FUTURE DIRECTIONS AND RESEARCH AGENDA

Synthesising the gaps identified across Sections 4 through 12, several priority directions for research, practice, and policy emerge.

13.1 Closing the Process-to-Outcome Evidence Gap

Because most CDSS and related instruments show stronger evidence for process-of-care improvement than for hard patient results, future studies should prioritise adequately powered, outcome-focused trials; comprising adverse-drug-event rates, hospitalisation, and mortality; alternatively than depending

primarily on process surrogates such as alert-acceptance rate.

13.2 Standardising Outcome Measurement

Reviews of CDSS effectiveness studies have repeatedly identified mixed and inconsistently specified outcome measures as an obstacle to synthesising evidence across studies; a standardised, consensus-based outcome framework for medication-safety technology evaluation would materially improve the comparability of future study.

13.3 External and Prospective Validation of AI Models

AI/ML pharmacovigilance and risk-prediction instruments need prospective, multi-site validation; comprising explicit assessment of performance across demographic subgroups; before broad clinical deployment, alongside persisted development of explainable-AI approaches that allow clinicians and regulators to audit model reasoning.

13.4 Human-Centred and Participatory Design

Persistent issues such as alert fatigue, BCMA workarounds, and low drug-library adherence in smart pumps point to an ordinary and widespread root reason: technology introduced without sufficient attention to frontline workflow and cognitive strain. Future implementations should embed human-factors proficiency and frontline clinician involvement from the design stage, not entirely at post-deployment evaluation.

13.5 Interoperability as Infrastructure

Achieving the closed-loop, auto-programming integration of EHR, CPOE, BCMA, and smart pumps described in Section 5 should be treated as basic and fundamental system investment instead than an optional upgrade, given uniform and unchanging evidence that interoperable configurations outperform standalone deployments of the identical technologies.

13.6 Responsible Scaling of Blockchain Traceability

Blockchain-based supply-chain traceability remains largely at pilot stage; study should focus on scalability, cross-organisational management models, and integration with existing pharmacy and logistics systems to move from proof-of-concept toward system capable of meaningfully minimizing substandard- and falsified-medicine damage.

13.7 Equity of Access, Including the Indian Rural-Urban Digital Divide

As RPM, digital therapeutics, and AI-enabled observing expand, attention is required to ensure that patients without dependable and trustworthy connection, digital literacy, or admittance to congruent and adaptable devices are not methodically excluded from these safety advantages, which could otherwise widen existing inequalities in therapy-related results. The irregular electronic-prescribing penetration and rural-urban linkage gap described for India in Section 9.5 is an explicit and immediate instance of this broader equity concern.

14. CONCLUSION

The evidence examined here supports a plain and understandable, if qualified, conclusion: digital innovation materially improves the safety of therapy implementation, but its advantage is neither automatic nor uniform. Clinical decision support systems, barcode medication administration, smart infusion pumps, AI-enabled pharmacovigilance, remote patient observation, digital therapeutics, and blockchain-based supply-chain traceability each address a distinct point of vulnerability in the therapy pathway, and each has generated encouraging evidence of advantage; most consistently for process-of-care measures, and more variably for hard patient results.

What differentiates successful from disappointing implementations, across virtually every domain examined, is not the sophistication of the underlying technology but the quality of its integration into true

clinical workflow: warning design that respects clinical judgement alternatively than overwhelming it; compatibility that eliminates instead than relocates manual transcription risk; AI models that is confirmed, explainable, and governed instead than deployed as opaque black boxes; and supply-chain innovations designed for the pragmatic realities of worldwide pharmaceutical distribution alternatively than for pilot-scale presentation solely.

The five-layer framework proposed in Section 10; data foundation, point-of-care execution, tracking and feedback, analytics and learning, and management; provides one way to organise this intricacy, and its central message is one of interdependence: a condition system's overall safety advantage from digital investment is bounded by its weakest layer, not its strongest single instrument. Future progress will rely less on the invention of new individual technologies and more on the disciplined, evidence-based, human-centred work of joining the technologies that already exist into safer, more reliable systems of care.

ACKNOWLEDGEMENTS

[The authors should insert here either a statement of the support received in preparing this review (e.g., institutional, library, or colleague assistance) or the sentence: 'No specific support was received in the preparation of this review.']

FUNDING

[The authors should insert here either the funding source and grant/award number, or the sentence: 'This review received no specific funding from any funding agency in the public, commercial, or not-for-profit sectors.']

AUTHOR CONTRIBUTIONS

[To be completed by the authors using a recognised taxonomy, e.g.: K. Jayasri Naga Suryamukhi — conceptualisation, literature search, drafting; P. Maitreya — conceptualisation, critical revision,

supervision. Both authors reviewed and approved the final manuscript.]

ETHICS STATEMENT

Not applicable — this review did not involve human participants or animals.

CONFLICT OF INTEREST

[The authors should insert here either a declaration of any financial or personal relationships that could be perceived to influence this work, or the sentence: ‘The authors declare that they have no conflict of interest.’ This statement must be completed before submission; it cannot be supplied on the authors’ behalf.]

REFERENCES

1. World Health Organization. Medication Without Harm – Global Patient Safety Challenge on Medication Safety. Geneva: WHO; 2017.
2. World Health Organization. Global Patient Safety Report 2024. Geneva: WHO; 2024.
3. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health System. Washington, DC: National Academies Press; 2000.
4. Makary MA, Daniel M. Medical error—the third leading cause of death in the US. *BMJ*. 2016;353:i2139. [A widely cited but methodologically contested extrapolation; see Section 1 for discussion of the surrounding critique.]
5. U.S. Food and Drug Administration. 24-Hour Summary of the Digital Health Advisory Committee: Total Product Lifecycle Considerations for Generative AI-Enabled Devices. Silver Spring, MD: FDA; meeting held 20–21 November 2024.
6. Lainer M, Mann E, Sönnichsen A. Information technology interventions to improve medication safety in primary care: a systematic review. *Int J Qual Health Care*. 2013;25(5):590–598.
7. Agency for Healthcare Research and Quality (AHRQ) Patient Safety Network. Clinical Decision Support Systems (Primer). Rockville, MD: PSNet; updated 2025.
8. Teich JM, Osheroff JA, Pifer EA, Sittig DF, Jenders RA. Clinical decision support in electronic prescribing: recommendations and an action plan. *J Am Med Inform Assoc*. 2005;12(4):365–376.
9. Jia P, Zhang L, Chen J, Zhao P, Zhang M. The effects of clinical decision support systems on medication safety: an overview. *PLoS One*. 2016;11(12):e0167683.
10. Ng Y, Hsu JTY, Ng NNE, et al. Evaluating the role of clinical decision support systems in medication safety for older people: a systematic review. *Age Ageing*. 2025;54(7):afaf206.
11. Damiani G, et al. Clinical decision support systems to improve drug prescription and therapy optimisation in clinical practice: a scoping review. *Front Public Health*. 2022. [Complete author list and volume/page details to be confirmed by the authors; the aggregator label ‘/ PMC’ has been removed from the journal name.]
12. Lampe D, Grosser J, Grothe D, et al. How intervention studies measure the effectiveness of medication safety-related clinical decision support systems in primary and long-term care: a systematic review. *BMC Med Inform Decis Mak*. 2024;24:188.
13. Kane-Gill SL, et al. Impact of a clinical decision support system on the efficiency and effectiveness of performing medication reviews in community pharmacies: a randomized controlled trial. *Pharmacy (Basel)*. 2024. [Complete author list and volume/page details to be confirmed by the authors.]
14. Ohashi K, Dalleur O, Dykes PC, Bates DW. Benefits and risks of using smart pumps to reduce medication error rates: a systematic review. *Drug Saf*. 2014;37(12):1011–1020.
15. DeVine SN, et al. Implementing barcode medication administration and smart infusion pumps is just the beginning of the safety journey to prevent administration errors. *Enferm Clin*. 2020;30(Suppl 1). [Complete author list and page numbers to be confirmed by the authors; please verify against the original Spanish-language source.]
16. [Authors to be confirmed]. The impact of smart pump interoperability on medication administration accuracy. *J Patient Saf*. 2022. [The source record supplied for this revision]

listed the journal name in the author position; the actual author names, volume, issue and pages could not be recovered from the metadata provided and must be confirmed by the authors before submission.]

17. American Nurse Journal. Infusion pumps — protecting patients through careful teamwork. *Am Nurse*. 2024. [Volume/issue/pages to be confirmed by the authors.]
18. American Nurse Journal. Understanding infusion pump technology and interoperability. *Am Nurse*. 2022. [Volume/issue/pages to be confirmed by the authors.]
19. Salas M, Petracek J, Yalamanchili P, et al. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. *Pharm Med*. 2022;36(5):295–306.
20. Falconer N, Barras M, Cottrell N. Systematic review of predictive risk models for adverse drug events in hospitalized patients. *Br J Clin Pharmacol*. 2018;84(5):846–864.
21. Vora M, et al. AI-driven pharmacovigilance: enhancing adverse drug reaction detection with deep learning and NLP. *Intell Pharm*. 2025. [Journal name corrected from an aggregator listing; complete author list and volume/page details to be confirmed by the authors.]
22. Schreier O, Yazdani A, Galdadas I, Kabak R, Gervasio FL, Mu G, Teodoro D. A scoping review of the application of artificial intelligence for the analysis of adverse drug events in clinical research. *medRxiv*. 2025. doi:10.1101/2025.07.14.25331486.
23. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. *Int J Clin Pharm*. 2025;47(4):932–944. doi:10.1007/s11096-025-01975-3.
24. Kompa B, Hakim JB, Palepu A, et al. Artificial intelligence based on machine learning in pharmacovigilance: a scoping review. *Drug Saf*. 2022;45(5):477–491.
25. Kang H, et al. Systematic review of AI-based models in pharmacoepidemiology for adverse drug event prediction and detection. *Front Drug Saf Regul*. 2026;6:1773186.
- [Complete author list to be confirmed by the authors.]
26. Klein DO, Renneberg RJMW, Koopman RJ, et al. A systematic review of the impacts of remote patient monitoring (RPM) interventions on safety, adherence, quality-of-life and cost-related outcomes. *NPJ Digit Med*. 2024;7:187.
27. Shaik T, Tao X, Higgins N, Li L, Gururajan R, Zhou X, Acharya UR. Remote patient monitoring using artificial intelligence: current state, applications, and challenges. *WIREs Data Min Knowl Discov*. 2023;13(2):e1485.
28. Smuck M, Odonkor CA, Wilt JK, Schmidt N, Swiernik MA. The emerging clinical role of wearables: factors for successful implementation in healthcare. *NPJ Digit Med*. 2021;4:45.
29. MacKinnon GE, Brittain EL. Mobile health technologies in cardiopulmonary disease. *Chest*. 2020;157(3):654–664.
30. Sakamaki T, Furusawa Y, Hayashi A, Otsuka M, Fernandez J. Remote patient monitoring for neuropsychiatric disorders: a scoping review. *Telemed J E Health*. 2022;28(9). [Pages to be confirmed by the authors.]
31. World Health Organization. A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products. Geneva: WHO; 2017.
32. Bhaskar S, et al. Blockchain technology in the pharmaceutical industry: a systematic review. 2022. [The source record supplied for this revision gave only the aggregator ‘PMC’ as the journal name; the actual journal, volume, issue and pages must be confirmed by the authors before submission.]
33. Mackey TK, Nayyar G. A review of existing and emerging digital technologies to combat the global trade in fake medicines. *Expert Opin Drug Saf*. 2017;16(5):587–602.
34. Ben Abdelghani S, Nabli H, Ben Djemaa R, Sliman L. Blockchain-integrated technologies to address counterfeit drugs in the pharmaceutical supply chain. In: Bajaj A, Mishra PM, Abraham A, eds. [book title to be confirmed by the authors]. Cham: Springer; 2025.
35. Kumar A, et al. Internet of things based blockchain for temperature monitoring and

- counterfeit pharmaceutical prevention. *Sensors* (Basel). 2020. [Volume, issue and pages to be confirmed by the authors; the aggregator label ‘/ PMC’ has been removed from the journal name.]
36. Musamih A, Salah K, Jayaraman R, Arshad J. Blockchain-based drug traceability in healthcare supply chain. *IEEE Access*. 2021;9:9728–9743.
37. National Health Authority, Government of India. Ayushman Bharat Digital Mission and Health Data Management Policy. New Delhi: NHA; 2022.
38. Ministry of Health and Family Welfare, Government of India. Telemedicine Practice Guidelines. New Delhi: MoHFW; 2020.
39. Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India (PvPI). Ghaziabad: IPC; ongoing programme, accessed 2026.
40. Government of India. The Drugs and Cosmetics Act, 1940, and Rules thereunder; Directorate General of Foreign Trade track-and-trace requirements for pharmaceutical exports.
41. Van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. *J Am Med Inform Assoc*. 2006;13(2):138–147.
42. Kesselheim AS, Cresswell K, Phansalkar S, Bates DW, Sheikh A. Clinical decision support systems could be modified to reduce ‘alert fatigue’ while still minimizing the risk of litigation. *Health Aff (Millwood)*. 2011;30(12):2310–2317.
43. Hussain MI, Reynolds TL, Zheng K. Medication safety alert fatigue may be reduced via interaction design and clinical role tailoring: a systematic review. *J Am Med Inform Assoc*. 2019;26(10):1141–1149.
44. Newton N, Bamgboje-Ayodele A, Forsyth R, Tariq A, Huang J, Yannam R, Lalor DJ, Sobey AJ, Baysari MT. Experiences of alert fatigue and its contributing factors in hospitals: qualitative study. *J Med Internet Res*. 2026;28:e78676.
45. U.S. Food and Drug Administration. 24 Hour Summary of the Digital Health Advisory Committee, November 20–21, 2024. Silver Spring, MD: U.S. Food and Drug Administration; 2024.
46. Powers EM, Shiffman RN, Melnick ER, Hickner A, Sharifi M. Efficacy and unintended consequences of hard-stop alerts in electronic health record systems: a systematic review. *J Am Med Inform Assoc*. 2018;25(11):1556–1566.
47. Sittig DF, Singh H. A new sociotechnical model for studying health information technology in complex adaptive healthcare systems. *Qual Saf Health Care*. 2010;19(Suppl 3):i68–i74.